JAZZ Nasdaq Russell 1000 Earnings call
Jazz Pharmaceuticals (JAZZ) · Q2 2026 results and valuation
Share price: $248.24 · 2026-11-11
Results Q2 2026 vs Q1 2026 · previous quarter · published 3 Aug 2026 and 6 May 2026
Net income down 34.2% on the previous quarter. Management sounded upbeat, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
−34.2%
Net income vs Q1 2026
Outlook given
Net income 192.8M vs 293.1M
Revenue +13.0%
2 · How management spoke
Upbeat
More upbeat than 71% of company calls
Answers to analysts: typical, in line with the script.
Similar to last call.
3 · What stood out Nothing unusual flagged this period.
Valuation
Is Jazz Pharmaceuticals undervalued?
Reverse DCF. Free cash flow from the last full fiscal year (2025-12-31), grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
At 5.3% growth a year (3-year revenue growth), the model's fair value is $291.75 a share — the stock trades 15% below it. Today's price assumes 3.3% growth a year.
Current price
$248.24
close of 2026-11-11
Market implies growth of iThe yearly free-cash-flow growth, for the next 10 years, that today’s share price already assumes. If you believe the company grows faster than this, the stock is cheap under this model; slower, and it is expensive.
+3.3% for 10 yrs
Fair value / share
$291.75
Buy below
$218.81
Price vs fair value
Undervalued 15%
Price vs buy-below price
Overvalued 13%
Read between the lines
-
Guidance
The company updated its guidance to expect total revenues in the range of $4.60 billion to $4.75 billion.
Source quote
“We now expect total revenues in the range of $4.60 billion to $4.75 billion.”
-
Figure
JAZZ generated record revenue of $1.2 billion, representing 16% year-over-year growth.
Source quote
“We delivered another outstanding quarter, generating record revenue of $1.2 billion representing 16% year-over-year growth.”
-
Fading
The company reported an impressive commercial performance to start the year, highlighting the development of zanidatamab and the FDA's recent acceptance of the sBLA for Ziihera.
Source quote
“In addition to our impressive commercial performance to start the year, we are urgently advancing the development of zanidatamab for patients... This performance reflects the discipline and consistent efforts of our teams working with clarity and purpose to support the physicians and patients we serve. The FDA recently accepted our sBLA for Ziihera under...”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“The outstanding execution of our field-based teams was reflected in record quarterly revenue of $1.21 billion, an increase of 16% over the second quarter of 2025, driven by 32% growth...”
“Our consistent execution reflects the focused strategy we outlined at the beginning of the year, expand our leadership in key therapeutic areas, advance differentiated innovation and create durable long-term value.”
“Our second quarter results demonstrated the strength and continued diversification of our product portfolio, delivering record quarterly revenue, including a 32% increase from our oncology products compared to 2Q '25...”
Full figures
USD · SEC EDGAR XBRL (10-Q, period end 2026-06-30)
| Metric | Q2 2026period end 2026-06-30 | Q1 2026period end 2026-03-31 | Change | Q2 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 1.21B | 1.07B | +13.0% | 1.05B | +15.5% |
| Operating income | 248.2M | 336.6M | −26.3% | -686.4M | Turned profit |
| Net income | 192.8M | 293.1M | −34.2% | -718.5M | Turned profit |
| EPS | 2.78 | 4.43 | −37.2% | -11.74 | Turned profit |
| P/E today 16.2 | 16.5 | 1718.6 | −1702.1 | 12-mo loss | — |
Topics
Most discussed now
- BTC has served for it more service for it is a powerful foundation for the next major growth phase in...
- Jazz Pharmaceuticals is entering a new phase of growth created by the opportunity to deliver clinically meaningful outcomes for patients…
- Its consistent execution reflects the focused strategy Jazz Pharmaceuticals outlined at the beginning of the year, expand its leadership in…
- As Jazz Pharmaceuticals approaches a significant milestone with the August 25 PDUFA date for zanidatamab in first-line HER2-positive…
- Across the business, Jazz Pharmaceuticals' teams are delivering key therapies to patients, advancing zanidatamab, and leveraging its…
Faded since Q1 2026
- Fading I do want to point out 2 smaller items that also contributed to growth this quarter.
- Dropped Countries to provide reference pricing for the U.S.
- Fading Of course, it has already demonstrated how effective it...
- Fading Jazz Pharmaceuticals' commercial teams generated double-digit growth across all its promoted brands and saw strong contributions from its…
Latest announcements
Official filings, newest first.
- Material agreement; New financial obligation · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Material agreement; New financial obligation; Unregistered share sale; Other events · SEC 8-K
- Other events · SEC 8-K
- Material agreement · SEC 8-K
- Regulation FD disclosure · SEC 8-K
- Results of operations · SEC 8-K
- Shareholder vote results · SEC 8-K